What's a pharma to do to keep new meds moving to market? Sell off as many of the old ones as possible, if the current trend is any clue—and Novartis has…

Newly bulked up by M&A, Mylan plans to cut a chunk of its workforce—perhaps up to 3,500 jobs—as it moves to retrench and refocus.

People with diabetes are waiting too long to discuss vision problems with their doctors, according to a new study funded by Bayer.

Celgene’s Revlimid just can’t catch a break in the chronic lymphocytic leukemia market—and one analyst isn’t sure it ever will.

World drug spending heads for $1.5 trillion by 2021, report says, as new meds drive spending—and pricing debate spreads.

Teva's generics CEO, Siggi Olafsson, is jumping ship at a critical time, and analysts fear that the $40.5 billion Actavis integration will go off the…

AZ’s lung cancer med Tagrisso, a key pillar in the company’s big sales ambitions, held off cancer growth for twice as long as chemo in a new phase 3 trial.

Sanofi has held firm on its M&A requirements since first quoting them last year: Bolt-ons all the way up to a buy a la its $20 billion Genzyme pickup.…

Pharma